News & Updates
Showing Multidisciplinary articles
Showing

Brepocitinib doses hold promise in treatment of psoriatic arthritis
Treatment with brepocitinib at 30 and 60 mg daily outperforms placebo at relieving signs and symptoms of psoriatic arthritis (PsA), with a safety profile consistent with that seen in other brepocitinib trials, according to data from a phase IIb study.

Which COVID-19 vaccine should SARDs patients on immunomodulators use?
Vaccination with either BNT162b2 or mRNA-1273 results in a comparable risk of breakthrough COVID-19 infection among patients with systemic autoimmune rheumatic diseases (SARDs) using immunomodulatory medication, a study has shown.

COVID vax fortifies defences against emerging omicron variants in previously infected youths
For children and adolescents who have been previously exposed to SARS-CoV-2 infection, vaccination with BNT162b2 appears to provide additional protection against omicron BA.4 or BA.5 and XBB variant infections, according to a study from Singapore.

12-year review of HK Breast Cancer Registry: Neoadjuvant chemo effective in stage ≥II, HER2-positive and triple-negative disease
A 12-year review of Hong Kong Breast Cancer Registry (HKBCR) records of patients diagnosed with breast cancer in 2006–2017 showed that neoadjuvant chemotherapy (NAC) was effective in tumour downstaging, with one-fifth of patients subsequently achieving pathological complete response (pCR) in the breast and axillary lymph nodes. Patients with HER2-positive (nonluminal) and triple-negative disease were most likely to achieve pCR.

Serum osteopontin levels predicts response to treatment in unresectable HCC
Among patients with unresectable hepatocellular carcinoma (HCC) scheduled to receive standard combination therapy with atezolizumab plus bevacizumab, those with high levels of serum osteopontin at baseline are likely to have poor response to treatment, as shown in a study.




